Keryx Biopharmaceuticals, Inc. reported unaudited and consolidated earnings results for the third quarter and nine months ended September 30, 2018. For the quarter, the company reported total revenues of $28,036,000 compared to $14,996,000 for the same period a year ago. Operating loss was $14,686,000 compared to $23,719,000 for the same period a year ago. Loss before income taxes were $16,995,000 compared to $23,478,000 for the same period a year ago. Net loss was $16,995,000 or $0.14 per basic and diluted share compared to $23,498,000 or $0.20 per basic and diluted share for the same period a year ago. For the nine months, the company reported total revenues of $75,536,000 compared to $41,959,000 for the same period a year ago. Operating loss was $57,589,000 compared to $70,679,000 for the same period a year ago. Loss before income taxes were $61,043,000 compared to $132,951,000 for the same period a year ago. Net loss was $60,409,000 or $0.50 per basic and diluted share compared to $133,011,000 or $1.18 per basic and diluted share for the same period a year ago.